Cll Pharma

Other

Panmedica S.a.

Panmedica

S. A. Panmedica

Virbac Sa

Orphit

Ccl Pharma

Laboratoires Panmedica

Claude Laruelle

Marcel Lepant

Bernard Raynier

Jamal Temsamani

Dominique Toselli

Ren&eacute; Gimet

No&euml;l Zakarian

Tino Dalto

Guy Derrieu

Thierry Breul

A PAT nonapeptide of formula EAKSQGGSD (SEQ ID NO: 1) can be used to treat or prevent neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Huntington's disease and amyotrophic lateral sclerosis. Pharmaceutical compositions containing the PAT nonapeptide can be formulated for administration by parenteral route, including the subcutaneous, intraperitoneal, intravenous or intranasal routes.

Use of the PAT nonapeptide in the treatment and prevention of neurodegenerative diseases

The invention refers to the use of the PAT nonapeptide which is a thymuline analog in the treatment of autoimmune diseases, in particular of rheumatoid arthritis and intestinal bowel diseases (IBD) such as the Crohn's disease.

Use of the pat nanopeptide in the treatment of autoimmune diseases

The invention relates to the use of the PAT nonapeptide in the manufacture of a drug for preventing or treating a neurodegenerative disease such as Alzheimer's disease. The parenteral route of administration is preferable, including the subcutaneous, intraperitoneal, intravenous or intranasal routes. The invention also relates to an injectable formulation containing the PAT nonapeptide which can be administered to patients suffering from a neurodegenerative disease such as Alzheimer's disease.

Use of the PAT nanopeptide in treating and preventing neurodegenerative diseases

The invention relates to non hemolytic compositions containing an antiplatelet agent such as clopidogrel or ticlopidine; these compositions being characterized in that the antiplatelet agent is in the form of free base, and the composition contains at least one hydrophilic non ionic surfactant. The invention relates also a galenic form, a method of preparation of thereof, as well as therapeutic uses of thereof, especially in patients who suffer from undesirable effects related to hemolysis and/or gastrointestinal acidity.

Oral composition containing an antiplatelet agent of the thienopyridine family in the form of free base

Galenic formulations fast disintegrating in the mouth and method for preparing same

The invention relates to dispersible tablets containing macrolides as active ingredients either on their own or associated with other active ingredients, in addition to a method for the production thereof. The dispersible tablets are characterized in that the macrolide is chosen from a group that is made up of pristinamycin, azithromycin, roxithromycin, clarithromycin and spiramycin, and is present in a basic form in proportions ranging from 20-60% of the total weight of said tablets. The dispersible tablets are also characterized in that they contain at least one disintegrator in proportions ranging from 1-25% of the total weight of said tablets in addition to at least one sweetening agent.

Dispersible macrolide compounds and method for production thereof

Soluble fenofibrate (Rec. INN) formulations exhibiting a significantly improved bioavailability after oral administration ('superbioavailability'), a process for their production and medicaments comprising these formulations. The said fenofibrate pharmaceutical dosage formulations essentially contain fenofibrate in solution in a solubilizing agent consisting of a non-ionic surfactant, diethylene glycol monoethyl ether (DGME).

Pharmaceutical dosage formulations of fenofibrate and their applications

Hydroquinone amino-acid esters, methods of preparation, and

3,3,5-trimethylcyclohexyl 2-methylpropionate derivatives, their method

Amino acid esters of cycloaliphatic alcohols of the formula: ##STR1## wherein A is cyclohexyl, cyclohexenyl, cyclopentyl, or cyclopentenyl, substituted with from one to three radicals selected from the group consisting of methyl, ethyl and ethenyl. These compounds are useful in treating lipemic disorders.

Amino acid esters of cycloaliphatic alcohols and their use in treating

A syringe guide with adjustment of the depth to which the needle penetrates, the guide comprising a body (4) having one end provided with a sliding base (1) which is adjustable in position by means of a screw (3), and whose other end includes a sliding part (6) fixed to the syringe (2) and loaded by a spring (9) which, on relaxing, causes the needle (11) to be plunged into the skin to a predetermined depth.

Spring impelled syringe guide with skin penetration depth adjustment

Amino acid esters of cycloaliphatic alcohols of the formula: ##STR1## wherein A is cyclohexyl, cyclohexenyl, cyclopentyl and cyclopentenyl, substituted with from one to three radicals which are methyl, ethyl, and/or ethenyl. These amino acid esters have hypolipemic properties.

Amino acid of cycloaliphatic alcohols, process for their preparation and

Device for subcutaneous injection without a needle

Drugs with high anticonvulsant and analgesic activities constituted by symmetrical .beta.-dialkoxyiminocycloalklene derivatives in which the imine double bonds are conjugated with the cyclic double bond or bonds belonging to one or more fused benzene rings. They correspond to the general formula I: ##STR1##

Symmetrical O-substituted dioximes of benzo-fused

Alkylcarboxamides of pyridylalkylamines, useful in human and verterinary medicine, correspond to the general formula I: ##STR1## wherein n=0 or 1,

Growing community of inventors

Villeneuve-Loubet, France

Claude Laruelle